NICE — Íàöèîíàëüíûé èíñòèòóò çäîðîâüÿ è êëèíè÷åñêîãî ñîâåðøåíñòâîâàíèÿ (êà÷åñòâà ìåäèöèíñêîé ïîìîùè) Âåëèêîáðèòàíèè (National Institute for Health and Clinical Excellence)
NK — åñòåñòâåííûå êëåòêè-êèëëåðû (natural killer)
NMDA — N-ìåòèë-D-àñïàðòàò (N-methyl-D-aspartate)
NMDA — N-ìåòèë-D-àñïàðòàòíûå ðåöåïòîðû
NNT — ÷èñëî áîëüíûõ, êîòîðûõ íåîáõîäèìî ïðîëå÷èòü, ÷òîáû äîñòè÷ü êàêîãî-òî óêàçàííîãî ýôôåêòà (Number Need to Treatment)
OR — îòíîøåíèå øàíñîâ (odds ratio)
paCO2 — ïàðöèàëüíîå äàâëåíèå óãëåêèñëîãî ãàçà â àðòåðèàëüíîé êðîâè
PALS — êóðñû ðàñøèðåííûõ ðåàíèìàöèîííûõ ìåðîïðèÿòèé â ïåäèàòðèè (Pediatric Advanced Life Support)
PANDAS — àóòîèììóííîå íåéðîïñèõèàòðè÷åñêîå ðàññòðîéñòâî â äåòñêîì âîçðàñòå, àññîöèèðîâàííîå ñî ñòðåïòîêîêêîâîé èíôåêöèåé (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
 õîäå ïîäãîòîâêè ñòàòåé ïî ãåíåòèêå â ïåäèàòðèè äëÿ ïîëüçîâàòåëåé ñàéòà ÌåäÓíèâåð èñïîëüçîâàíû òðóäû ñëåäóþùèõ àâòîðîâ:
Abdul-Karim R, Berkman BE, Wendler D, et al. Disclosure of incidental findings from next-generation sequencing in pediatric genomic research. Pediatrics. 2013;131:564–571.
ACMG Board of Directors: Points to consider in the clinical application of genomic sequencing. Genet Med. 2012;14:759–761.
Ali-Khan SE, Daar AS, Shuman C, et al. Whole genome scanning: resolving clinical diagnosis and management amidst complex data. Pediatr Res. 2009;66:357–363.
Alkan C, Kidd J, Marques-Bonet T, et al. Personalized copy number and segmental duplication maps using next-generation sequencing. Nat Genet. 2009;41:1061–1067.
Alliance of Genetic Support Groups. Directory of National Genetic Voluntary Organizations. 35 Wisconsin Circle, Suite 440, Chevy Chase, MD 20815–27015.
Bartels DM, LeRoy BS, McCarthy P, et al. Nondirectiveness in genetic counseling: a survey of practitioners. Am J Med Genet. 1997;72:172–179.
Bick D, Dimmock D. Whole exome and whole genome sequencing. Curr Opin Pediatr. 201123:594–600.
De la Torre R., de Sola S., Hernandez G. et al. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down’s syndrome (TESDAD): a double-blind, randomizes, placebo-controlled, phase 2 trial // Lancet Neurol. 2016. Vol. 15. P. 801–810.
Dennis J., Archer N., Ellis J. et al. Recognising heart disease in children with Down syndrome // Arch. Dis. Child Educ. Pract. Ed. 2010. Vol. 95. N. 4. P. 98–104.
Dykens E.M. Psychiatric and behavioral disorders in persons with Down syndrome // Ment. Retard. Dev. Disabil. Res. Rev. 2007. Vol. 13. P. 272–278.
Ehrich M., Deciu C., Zwiefelhofer T. et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting // Am. J. Obstet. Gynecol. 2011. Vol. 204. N. 3. P. 205.e1–11.
Garrison M.M., Jeffries H., Christakis D.A. Risk of death for children with Down syndrome and sepsis // J. Pediatr. 2005. Vol. 147. P. 748–752.
Gibson P.A., Newton R.W., Selby K. et al. Longitudinal study of thyroid function in Down’s syndrome in the first two decades // Arch. Dis. Child. 2005. Vol. 90. P. 574–578.
Hanney M., Prasher V., Williams N. et al. Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomized, double-blind, placebo-controlled trial // Lancet. 2012. Vol. 379. P. 528–536.
Irving C., Basu A., Richmond S. et al. Twenty-year trends in prevalence and survival of Down syndrome // Eur. J. Hum. Genet. 2008. Vol. 16. P. 1336–1340.
Janvier A., Farlow B., Wilfond B.S. The experience of families with children with trisomy 13 and 18 in social networks // Pediatrics. 2012. Vol. 130. P. 293–298.
Juj H., Emery H. The arthropathy of Down syndrome: an undiagnosed and under-recognized condition // J. Pediatr. 2009. Vol. 154. P. 234–238.
Kaneko Y., Kobayashi J., Achiwa I. et al. Cardiac surgery in patients with trisomy 18 // Pediatr. Cardiol. 2009. Vol. 30. P. 729–734.
Kennedy J.P.Jr., Foundation for the Benefit of Persons with Intellectual Disabilities: Special Olympics coaching guides. 2004. www.specialolympics.org.
Kumada T., Miyajima T., Fujii T. Whorled eyebrows: a common facial feature of children with trisomy 18 // J. Pediatr. 2012. Vol. 161. P. 962–963.
Lantos J.D. Trisomy 13 and 18: treatment decisions in a stable gray zone // JAMA. 2016. Vol. 316. P. 396–398.
Lin H.Y., Lin S.P., Chen Y.J. et al. Clinical characteristics and survival of trisomy 18 in a medical center in Taipei, 1988–2004 // Am. J. Med. Genet. 2006. Vol. 140A. P. 945–951.
Lorenz J.M., Hardart G.E. Evolving medical and surgical management of infants with trisomy 18 // Curr. Opin. Pediatr. 2014. Vol. 26. P. 169–176.
Marild K., Stephansson O., Grahnquist L. et al. Down syndrome is associated with elevated risk of celiac disease: a nationwide case-control study // J. Pediatr. 2013. Vol. 163. P. 237–242.
McCabe L.L., Hickey F., McCabe E.R.B. Down syndrome: addressing the gaps // J. Pediatr. 2011. Vol. 159. P. 525–526.
McDowell K.M., Craven D.I. Pulmonary complications of Down syndrome during childhood // J. Pediatr. 2011. Vol. 158. P. 319–325.
Merritt T.A., Catlin A., Wool C. et al. Trisomy 18 and trisomy 13: treatment and management decisions // Neoreviews. 2012. Vol. 13. P. e40–e48.
Nelson K.E., Hexem K.R., Feudtner C. Inpatient hospital care of children with trisomy 13 and trisomy 18 in the United States // Pediatrics. 2012. Vol. 129. P. 869–876.
Nelson K.E., Rosella L.C., Mahant S., Gutterman A. Survival and surgical interventions for children with trisomy 12 and 18 // JAMA. 2016. Vol. 316. P. 420–428.
Nicolaides K.H., Wright D., Poon C. et al. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing // Ultrasound Obstet. Gynecol. 2013. Vol. 42. P. 41–50.
Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341:1233158.
Bowles-Biesecker B, Marteau TM. The future of genetic counseling: an international perspective. Nat Genet. 1999;22:133–137.
Brunner HG. The variability of genetic disease. N Engl J Med. 2012;367:1350–1352.
Burn J, Flinter F. Should we sequence everyone’s genome? BMJ. 2013;346:16–17.
Caga-anan ECF, Smith L, Sharp RR, et al. Testing children for adult-onset genetic diseases. Pediatrics. 2012;129:163–167.
Chen LP, Beck AE, Tsuchiya KD, et al. Institutional protocol to manage consanguinity detected by genetic testing in pregnancy in a minor. Pediatrics. 2015;135(3):e736–e739.
Cohen IG, Adashi EY. Preventing mitochondrial DNA diseases one step forward, two steps back. JAMA. 2016;316:273–274.
Collins FS, Hamburg MA. First FDA authorization for next-generation sequencer. N Engl J Med. 2013;369:2369–2371.
Edwards JG, Feldman G, Goldberg J, et al. Expanded carrier screening in reproductive medicine: points to consider. Obstet Gynecol. 2015;125:653–662.
Evans JP, Berg JS. Next-generation DNA sequencing, regulation, and the limits of paternalism. JAMA. 2011;306:2376–2377.
Falk MJ, Decherney A, Kahn JP. Mitochondrial replacement techniques: implications for the clinical community. N Engl J Med. 2016;374:1103–1106.
Fallat ME, Katz AL, Mercurio MR, et al. Ethical and policy issues in genetic testing and screening of children. Pediatrics. 2013;131:620–622.
Farrell MH, Certain LK, Farrell PM. Genetic counseling and risk communication services of newborn screening programs. Arch Pediatr Adolesc Med. 2001;155:120–126.
GeneTests
Green RC, Lupski JR, Biesecker LG. Reporting genomic sequencing results to ordering clinicians. JAMA. 2013;310:365–366.
Grody WW. Where to draw the boundaries for prenatal carrier screening. JAMA. 2016;316:717–719.
Haque IS, Lazarin GA, Kang P, et al: Modeled fetal risk of genetic diseases identified by expanded carrier screening. JAMA. 2016;316:734–742.
Hardy J, Singleton A. Genomewide association studies and human disease. N Engl J Med. 2009;360:1759–1768.
Hirschorn JN. Genomewide association studies — illuminating biologic pathways. N Engl J Med. 2009;360:1699–1701.
Holtzman NA, Watson MS. Promoting safe and effective genetic testing in the United States: final report of the task force on genetic testing. Bethesda, MD, 1997. Human Genome Research Institute.
Hynes RO, Coller BS, Porteus M. Toward responsible human genome editing. JAMA. 2017;317:1829–1830.
Jacob HJ, Abrams K, Bick DP, et al. Genomics in clinical practice: lessons from the front lines. Sci Transl Med. 2013;5:194.
Klitzman R, Appelbaum PS, Chung W. Return of secondary genomic findings vs patient autonomy. JAMA. 2013;310:369–370.
Komaroff AL. Gene editing using CRISPR: why the excitement? JAMA. 2017;318:699–700.
Korf BR, Rehm HL. New approaches to molecular diagnosis. JAMA. 2013;309:1511–1520.
Kuehn BM. Growing use of genomic data reveals need to improve consent and privacy standards. JAMA. 2013;309:2083–2084.
Li MM, Andersson HC. Clinical application of microarray-based molecular cytogenetics: an emerging new era of genomic medicine. J Pediatr 2009;155:311–317.
Ma H, Marti-Gutierrez N, Park SW, et al: Correction of a pathogenic gene mutation in human embryos. Nature. 2017;548:413–419.
Manolio TA. Cohort studies and genetics of complex disease. Nat Genet. 2009;41:5–6.
May T, Zusevics KL, Strong KA. On the ethics of clinical whole genome sequencing of children. Pediatrics. 2013;132:207–209.
Morain S, Greene MF, Mello MM. A new era in noninvasive prenatal testing. N Engl J Med. 2013;369:499–501.
Naldini L. Gene therapy returns to centre stage. Nature. 2015;526:351–360.
Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994–2004.
Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015;372:1589–1597.
Ormond KE, Mortlock DP, Scholes DT, et al. Human germline genome editing. Am J Hum Genet. 2017;101:167–176.
Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med. 2015;66:471–486.
Presidental Commission for the Study of Bioethical Issues. Anticipate and communicate: ethical management of incidental and secondary findings in the clinical, research, and direct-to-consumer contexts, December 2013.
Public Health Directorate/Health Science and Bioethics Division: Draft regulations to permit the use of new treatment techniques to prevent the transmission of a serious mitochondrial disease from mother to child, Crown, UK, July 2014.
Ross LF, Rothstein MA, Clayton EW. Mandatory extended searches in all genome sequencing: incidental findings, patient autonomy, and shared decision making. JAMA. 2013;310:367–368.
Snyder MW, Simmons LE, Kitzman JO, et al. Copy-number variation and false positive prenatal aneuploidy screening results. N Engl J Med. 2015;372:1639–1645.
Solomon BD, Hadley DW, Pineda-Alvarez DE, et al. Incidental medical information in whole-exome sequencing. Pediatrics. 2012;129:e1605–e1611.
Tim-Aroon T, Harmon HM, Nock ML, et al. Stopping parenteral nutrition for 3 hours reduces false positives in newborn screening. J Pediatr. 2015;167:312–316.
Verlinsky Y, Rechitsky S, Sharapova T, et al. Preimplantation HLA testing. JAMA. 2004;291:2079–2085.
Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373:220–231.
Wright CF, Middleton A, Burton H, et al. Policy challenges of clinical genome sequencing. BMJ. 2013;347:20–23.
Yazdi SMZ, Robin NH. We need to know our limitations: genetic testing for complex traits. Curr Opin Pediatr. 2013;25:643–644.
Ñïè American Academy of Pediatrics, Committee on Bioethics and Committee on Genetics; American College of Medical Genetics and Genomics, Social, Ethical and Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Pediatrics. 2013;131:620–622.
Baird PA, Anderson TW, Newcombe HB, et al. Genetic disorders in children and young adults: a population study. Am J Hum Genet. 1988;42:677–693.
Centers for Disease Control and Prevention. CDC Grand rounds: newborn screening and improved outcomes. MMWR Morb Mortal Wkly Rep. 2012;61:390–393.
Dauber A, Stoler J, Hechter E, et al. Whole exome sequencing reveals a novel mutation in CUL7 in a patient with an undiagnosed growth disorder. J Pediatr. 2013;162:202–204.
Friedman Ross L, Rothstein MA, Wright Clayton E. Mandatory extended searches in all genome sequencing: “incidental findings,” patient autonomy, and shared decision making. JAMA. 2013;310(4):367–368.
Greely HT. Banning genetic discrimination. N Engl J Med. 2005;353:865–867.
Hahn S, H?sli I, Lapaire O. Non-invasive prenatal diagnostics using next generation sequencing: technical, legal and social challenges. Expert Opin Med Diagn. 2012;6(6):517–528.
Hall JG, Powers EK, McLlvaine RT, et al. The frequency and financial burden of genetic disease in a pediatric hospital. Am J Med Genet. 1978;1:417.
McCandless SE, Brunger JW, Cassidy SB. The burden of genetic disease on inpatient care in a children’s hospital. Am J Hum Genet. 2004;74:121–127.
May T, Zusevics KL, Strong KA. On the ethics of clinical whole genome sequencing of children. Pediatrics. 2013;132:207–209.
Miller JW. Preliminary results of gene therapy for retinal degeneration. N Engl J Med. 2008;358:2282–2284.
Qasim W, Gaspar HB, Thrasher AJ. Update on clinical gene therapy in childhood. Arch Dis Child. 2007;92:1028–1031.
Stankiewicz P, Lupski JR. Structural variation in the human genome and its role in disease. Annu Rev Med. 2010;61:437–455.
Ali-khan SE, Daar AS, Shuman C, et al. Whole genome scanning: resolving clinical diagnosis and management amidst complex data. Pediatr Res. 2009;66:357–363.
Alkan C, Kidd JM, Marques-Bonet T, et al. Personalized copy number and segmental duplication maps using next-generation sequencing. Nat Genet. 2009;41:1061–1067.
Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet. 2010;375:1525–1535.
Bredenoord A, Braude P. Ethics of mitochondrial gene replacement: from bench to bedside. BMJ. 2011;342:87–89.
Christensen K, Murray JC. What genome-wide association studies can do for medicine. N Engl J Med. 2007;356:1094–1097.
Cordell HJ, Clayton DG. Genetic association studies. Lancet. 2005;366:1121–1130,.
Crotwell PL, Hoyme HE. Advances in whole-genome genetic testing: from chromosomes to microarrays. Curr Probl Pediatr Adolesc Health Care. 2012;42:47–73,.
Ellison JW, Ravnan B, Rosenfeld JA, et al. Clinical utility of chromosomal microarray analysis. Pediatrics. 2012;130:e1085–e1095,.
Ezkurdia I, Juan D, Rodriguez JM, et al. Multiple evidence strands suggest that there may be as few as 19,000 human protein-coding genes. Hum Mol Genet. 2014;23:5866–5878,.
Goldstein DB. Common genetic variation and human traits. N Engl J Med. 2009;360:1696–1698,.
Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363:301–304,.
Hardy J, Singleton A. Genomewide association studies and human disease. N Engl J Med. 2009;360:1759–1768,.
Hingorani AD, Shah T, Kumari M, et al. Translating genomics into improved healthcare. BMJ. 2010;341:1037–1042,.
Jacob HJ, Abrams K, Bick DP, et al. Genomics in clinical practice: lessons from the frontlines. Sci Transl Med. 2013;5: 194 cm5.
Lucassen A, Parker M. Confidentiality and sharing genetic information with relatives. Lancet. 2010;375:1507–1509.
McCarroll SA. Copy number variation and human genome maps. Nat Genet. 2010;42:365–366.
Moskowitz SA, Chmiel JF, Sternen DL, et al. CFTR-related disorders. In GeneReviews at GeneTests: Medical Genetics Information Resource (database online), 2008.
Shaw CJ, Lupski JR. Implications of human genome architecture for rearrangement-based disorders: the genomic basis of disease. Hum Mol Genet. 2004;13:R57–R64.
Wain LV, Armour JAL, Tonin MD. Genomic copy number variation, human health, and disease. Lancet. 2009;374:340–350.
Bennett RL, French KS, Resta RG, et al. Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. J Genet Couns. 2008;17:424–433.
Bittles AH. Consanguineous marriages and congenital anomalies. Lancet. 2013382:1316–1317,.
Choi JK, Kim YJ. Epigenetic regulation and the variability of gene expression. Nat Genet. 2008;40:141–147,.
Cree LM, Samuels DC, Chuva de Sousa Lopes S, et al. A reduction of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes. Nat Genet. 2008;40:249–254,.
Di Meo I, Lamperti C, Tiranti V. Mitochondrial diseases caused by toxic compound accumulation: from etiopathology to therapeutic approaches. EMBO Mol Med. 2015;7:1257–1266,.
Escames G, L?pez LC, Garc?a JA, et al: Mitochondrial DNA and inflammatory diseases. Hum Genet. 2012;131:161–173,.
Haas RH, Parikh S, Falk MJ, et al. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab. 2008;94:16–37,.
JAMA. Glossary of genomics terms. JAMA. 2013;309:1533–1535,.
Montero R, Yubero D, Villarroya J, et al. GDF-15 is elevated in children with mitochondrial diseases and is induced by mitochondrial dysfunction. PLoS ONE. 2016;11:e0148709,.
Nelson DL, Orr HT, Warren ST. The unstable repeats — three evolving faces of neurologic disease. Neuron. 2013;77:825–843,.
Rahman S. Gastrointestinal and hepatic manifestations of mitochondrial disorders. J Inherit Metab Dis. 2013;36:659–673,.
Samuels DC, Li C, Li B, et al. Recurrent tissue-specific mtDNA mutations are common in humans. PLoS Genet. 2016;9(11):e1003929,.
Schafer AM, Walker M, Turnbull DN, Taylor RW. Endocrine disorders in mitochondrial disease. 2013;Mol Cell Endocrinol. 379:2–11,.
ACOG Practice Bulletin. Screening for fetal chromosomal abnormalities // Obstet. Gynecol. 2007. Vol. 109. P. 217–227.
Bejjani B.A., Saleki R., Ballif B.C. et al. Use of targeted array-based CGH for the clinical diagnosis of chromosomal imbalance: is less more? // Am. J. Med. Genet. 2005. Vol. 134A. P. 259–267.
Bianchi D.W., Platt L.D., Goldberg J.D. et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing // Obstet. Gynecol. 2012. Vol. 119. P. 890–901.
Dugoff L. Application of genomic technology in prenatal diagnosis // N. Engl. J. Med. 2012. Vol. 367. P. 2249–2251.
Li M.M., Andersson H.C. Clinical application of microarray-based molecular cytogenetics: an emerging new era of genomic medicine // J. Pediatr. 2009. Vol. 155. P. 311–317.
Papenhausen P., Schwartz S., Risheg H. et al. UPD detection using homozygosity profiling with a SNP genotyping microarray // Am. J. Med. Genet. 2011. Vol. 155A. P. 757–768.
Robin N.H., Shprintzen R.J. Defining the clinical spectrum of deletion 22q11.2 // J. Pediatr. 2005. Vol. 147. P. 90–96.
Sahoo T., del Gaudio D., German J.R. et al. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster // Nat. Genet. 2008. Vol. 40. P. 719–721.
Sharp A.J., Mefford H.C., Li K. et al. A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures // Nat. Genet. 2008. Vol. 40. P. 322–328.
Stafler P., Wallis C. Prader-Willi syndrome: who can have growth hormone? // Arch. Dis. Child. 2008. Vol. 93. P. 341–345.
Vissers L.E.L.M., van Ravenswaaji C.M.A., Admiraal R. et al. Mutations in a new member of the chromodomain gene family cause CHARGE syndrome // Nat. Genet. 2004. Vol. 36. P. 955–957.
Walter S., Sandig K., Hinkel G.K. et al. Subtelomere FISH in 50 children with mental retardation and minor anomalies, identified by a checklist, selects 10 rearrangements including a de novo balanced translocation of chromosomes 17p13.3 and 20q13.33 // Am. J. Med. Genet. 2004. Vol. 128A. P. 364–373.
Youings S., Ellis K., Ennis S. et al. A study of reciprocal translocations and inversions detected by light microscopy with special reference to origin, segregation, and recurrent abnormalities // Am. J. Med. Genet. 2004. Vol. 126A. P. 46–60.
Yu S., Graf W.D., Shprintzen R.J. Genomic disorders on chromosome 22 // Curr. Opin. Pediatr. 2012. Vol. 24. P. 665–671.
Bardsley M.Z., Kowal K., Levy C. et al. 47,XYY syndrome: clinical phenotype and timing of ascertainment // J. Pediatr. 2013. Vol. 163. P. 1085–1094.
Binder G., Grathwol S., von Loeper K. et al. Health and quality of life in adults with Noonan syndrome // J. Pediatr. 2012. Vol. 161. P. 501–505.
Gault E.J., Perry R.J., Cole T.J. et al. Effect of oxandrolone and timing of pubertal induction on final height in Turner’s syndrome: randomized, double blind, placebo controlled trial // BMJ. 2011. Vol. 342. P. 907.
Lanfranco F., Kamischke A., Zitzmann M. et al. Klinefelter’s syndrome // Lancet. 2004. Vol. 364. P. 273–283,
Lee B.H., Kim J.M., Jin H.Y. et al. Spectrum of mutations in Noonan syndrome and their correlation with phenotypes // J. Pediatr. 2011. Vol. 159. P. 1029–1035.
Lin A.E. Focus on the heart and aorta in Turner syndrome // J. Pediatr. 2007. Vol. 150. P. 572–574.
Massa G., Verlinde F., De Schepper J. et al. Trends in age at diagnosis of Turner syndrome // Arch. Dis. Child. 2005. Vol. 90. P. 267–268.
Mazzanti L., Cicognani A., Baldazzi L. et al. Gonadoblastoma in Turner syndrome and Y chromosome–derived material // Am. J. Med. Genet. 2005. Vol. 135A. P. 150–154.
Roberts A.E., Allanson J.E., Tartaglia M. et al. Noonan syndrome // Lancet. 2013. Vol. 381. P. 333–340.
Petherick A. Cell-free DNA screening for trisomy is rolled out in Israel // Lancet. 2013. Vol. 382. P. 846.
Saugier-Veber P., Girard-Lemaire F., Rudolf G. et al. Genetic compensation in a human genomic disorder // N. Engl. J. Med. 2009. Vol. 360. P. 1211–1216.
Wapner R.J., Martin C.L., Levy B. et al. Chromosomal microarray versus karyotyping for prenatal diagnosis // N. Engl. J. Med. 2012. Vol. 367. P. 2175–2184.
Arnell H., Fischler B. Population-based study of incidence and clinical outcome of neonatal cholestasis in patients with Down syndrome // J. Pediatr. 2012. Vol. 161. P. 899–902.
Baum R.A., Nash P.L., Foster J.E.A. et al. Primary care of children and adolescents with Down syndrome: an update // Curr. Probl. Pediatr. Adolesc. Health Care. 2008. Vol. 38. P. 235–268.
Bull M.J. Committee on Genetics: Clinical report–health supervision for children with Down syndrome // Pediatrics. 2011. Vol. 128. P. 393–406.
Carey J.C. Perspectives on the care and management of infants with trisomy 18 and trisomy 13: striving for balance // Curr. Opin. Pediatr. 2012. Vol. 24. P. 672–678.
Carter M., McCaughey E., Annaz D. et al. Sleep problems in a Down syndrome population // Arch. Dis. Child. 2009. Vol. 94. P. 308–310.
Chiu R.W.K., Akolekar R., Zheng Y.W.L. et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study // BMJ. 2011. Vol. 342. P. 217.
Cicero S., Bindra R., Rembouskos G. et al. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free ?-hCG and PAPP-A at 11 to 14 weeks // Prenat. Diagn. 2003. Vol. 23. P. 306–310.
Norton M.E., Jacobsson B., Swamy G.K. et al. Cell-free DNA analysis for noninvasive examination of trisomy // N. Engl. J. Med. 2015. Vol. 372. N. 17. P. 1589–1597.
Papageorgiou E.A., Karagrigoriou A., Tsaliki E. et al. Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21 // Nat. Med. 2011. Vol. 17. P. 510–514.
Rasmussen S.A., Whitehead N., Collier S.A. et al. Setting a public health research agenda for Down syndrome: summary of a meeting sponsored by the CDC and the National Down Syndrome Society // Am. J. Med. Genet. 2008. Vol. 46A. P. 2998–3010.
Roizen N.J., Magyar C.I., Kuschner E.S. et al. A community cross-sectional survey of medical problems in 440 children with Down syndrome in New York state // J. Pediatr. 2014. Vol. 164. P. 871–876.
Shin M., Besser L.M., Kucik J.E. et al. Prevalence of Down syndrome among children and adolescents in 10 regions of the United States // Pediatrics. 2009. Vol. 124. P. 1565–1571.
Shott S.R., Amin R., Chini B. et al. Obstructive sleep apnea: should all children with Down syndrome be tested? // Arch. Otolaryngol. Head Neck Surg. 2006. Vol. 132. P. 432–436.
Van Gameren-Oosterom H.B.M., Fekkes M., van Wouwe J.P. et al. Problem behavior of individuals with Down syndrome in a nationwide cohort assessed in late adolescence // J. Pediatr. 2013. Vol. 163. P. 1396–1401.
Webb D., Roberts I., Vyas P. Haematology of Down syndrome // Arch. Dis. Child. 2007. Vol. 92. P. F503–F507.
Weijerman M.E., Van Furth M., Noordegraaf A.V. et al. Prevalence, neonatal characteristics, and first-year mortality of Down syndrome: a national study // J. Pediatr. 2008. Vol. 152. P. 15–19.
Wouters J., Weijerman M.E., Van Forth A.M. et al. Prospective human leukocyte antigen, endomysium immunoglobulin A antibodies, and transglutaminase antibodies testing for celiac disease in children with Down syndrome // J. Pediatr. 2009. Vol. 154. P. 239–242.
Bassett A.S., McDonald-McGinn D.M., Devriendt K. et al. Practical guidelines for managing patients with 22q11.2 deletion syndrome // J. Pediatr. 2011. Vol. 159. P. 332–339.
Battaglia A., Hoyme H.E., Dallapiccola B. et al. Further delineation of deletion 1p36 syndrome in 60 patients: a recognizable phenotype and common cause of developmental delay and mental retardation // Pediatrics. 2008. Vol. 121. P. 404–410.
Calado R.T., Young N.S. Telomere diseases // N. Engl. J. Med. 2009. Vol. 361. P. 2353–2365.
Fillion M., Deal C., Van Vliet G. Retrospective study of the potential benefits and adverse events during growth hormone treatment in children with Prader-Willi syndrome // J. Pediatr. 2009. Vol. 154. P. 230–233.
Gicquel C., Rossignol S., Cabrol S. et al. Epimutation of the telomeric imprinting center region on chromosome 11p15 in Silver-Russell syndrome // Nat. Genet. 2005. Vol. 37. P. 1003–1007.
Mefford H., Shapr A., Baker C. et al. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes // N. Engl. J. Med. 2008. Vol. 359. P. 1685–1698.
Peters J. Prader-Willi and snoRNAs // Nat. Genet. 2008. Vol. 40. P. 688–689.
Rappold G.A., Shanske A., Saenger P. All shook up by SHOX deficiency // J. Pediatr. 2005. Vol. 147. P. 422–424.
Romano A.A., Allanson J.E., Dahlgren J. et al. Noonan syndrome: clinical features, diagnosis, and management guidelines // Pediatrics. 2010. Vol. 126. P. 746–759.
Sybert V.P., McCauley E. Turner’s syndrome // N. Engl. J. Med. 2004. Vol. 351. P. 1227–1238.
Zeger M.P.D., Zinn A.R., Lahlou N. et al. Effect of ascertainment and genetic features on the phenotype of Klinefelter syndrome // J. Pediatr. 2008. Vol. 152. P. 716–722.
Abrams L., Cronister A., Brown W.T. et al. Newborn, carrier, and early childhood screening recommendations for fragile X // Pediatrics. 2012. Vol. 130. P. 1126–1135.
Dobkin C., Radu G., Ding X.H. et al. Fragile X prenatal analyses show full mutation females at high risk for mosaic Turner syndrome: fragile X leads to chromosome loss // Am. J. Med. Genet. 2009. Vol. 149A. P. 2152–2157.
Hersh J.H., Saul R.A. Committee on Genetics: Clinical report—health supervision for children with fragile X syndrome // Pediatrics. 2011. Vol. 127. P. 994–1006.
Hess L.G., Fitzpatrick S.E., Nguyen D.V. et al. A randomized, double-blind, placebo-controlled trial of low-dose sertraline in young children with fragile X syndrome // J. Dev. Behav. Pediatr. 2016. Vol. 37. P. 619–628.
Jacquemont S., Curie A., des Portes V. et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056 // Sci. Transl. Med. 2011. Vol. 3. P. 64ra1.
Jacquemont S., Hagerman R.J., Hagerman P.J. et al. Fragile-X syndrome and fragile X–associated tremor/ataxia syndrome: two faces of FMRI // Lancet Neurol. 2007. Vol. 6. P. 45–55.
Kidd S.A., Lachiewicz A., Barbouth D. et al. Fragile X syndrome: a review of associated medical problems // Pediatrics. 2014. Vol. 134. P. 995–1005.
Leigh M.J.S., Nguyen D.V., Mu Y. et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome // J. Dev. Behav. Pediatr. 2013. Vol. 34. P. 147–155.
Michalon A., Sidorov M., Ballard T.M. et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice // Neuron. 2012. Vol. 74. P. 49–56.
Jirtle RL: The Agouti mouse: a biosensor for environmental epigenomics studies investigating the developmental origins of health and disease, Epigenomics 6(5):447–450, 2014.
Lintas C, Persico AM: Unraveling molecular pathways shared by Kabuki and Kabuki-like syndromes, Clin Genet 2017.
Michels KB, Binder AM, Dedeurwaerder S, et al: Recommendations for the design and analysis of epigenome-wide association studies, Nat Meth 10(10):949–955, 2013.
Richmond RC, Sharp GC, Ward ME, et al: DNA methylation and BMI: investigating identified methylation sites at HIF3A in a causal framework, Diabetes 65(5):1231–1244, 2016.
Adams DR, Sincan M, Fuentes Fajardo K, et al: Analysis of DNA sequence variants detected by high-throughput sequencing, Hum Mutat 33:599–608, 2012.
Bordini BJ, Stephany A, Kliegman R: Overcoming diagnostic errors in medical practice, J Pediatr 185:19–25, 2017.
ClinVar: National Center for Biotechnology Information, US National Library of Medicine.
Gahl WA: The power of an undiagnosed disease program in a clinical research enterprise. In Gallin JI, Ognibene F, editors: Principles and practice of clinical research, Philadelphia, 2012, Elsevier, pp 701–705.
Gahl WA, Markello TC, Toro C, et al: The NIH Undiagnosed Diseases Program: insights into rare diseases, Genet Med 14:51–59, 2012.
Gahl W, Wise A, Ashley EA: The Undiagnosed Diseases Network of the NIH: a national extension, JAMA 314:1797–1798, 2015.
Garwell KD, Shahmirzadi L, El-Khechen D, et al: Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions, Genetics Med E-pub, November 2014.
Lee H, Deignan JL, Dorrani N, et al: Clinical exome sequencing for genetic identification of rare mendelian disorders, JAMA 312:1880–1887, 2014.
Lu JT, Campeau PM, Lee BH: Genotype-phenotype correlation: promiscuity in the era of next-generation sequencing, N Engl J Med 371:593–596, 2014.
Markello TC, Carlson-Donohoe H, Sincan M, et al: Sensitive quantification of mosaicism using high-density SNP arrays and the cumulative distribution function, Mol Genet Metab 105:665–671, 2012.
Markello TC, Han T, Carlson-Donohoe H, et al: Recombination mapping using Boolean logic and high-density SNP genotyping for exome sequence filtering, Mol Genet Metab 105:382–389, 2012.
Paribello C., Tao L., Folino A. et al. Open-label add-on treatment trial of minocycline in fragile X syndrome // BMC Neurol. 2010. Vol. 10. P. 91.
Raspa M., Wheeler A.C., Riley C. Public health literature review of fragile X syndrome // Pediatrics. 2017. Vol. 139. P. e20161159.
Rooms L., Kooy R.F. Advances in understanding fragile X syndrome and related disorders // Curr. Opin. Pediatr. 2011. Vol. 23. P. 601–606.
Wheeler A., Raspa M., Hagerman R. et al. Implications of the FMR1 prematutation for children, adolescents, adults, and their families // Pediatrics. 2017. Vol. 139. P. e20161159.
Al-Saleh S., Al-Naimi A., Hamilton J. et al. Longitudinal evaluation of sleep-disordered breathing in children with Prader-Willi syndrome during 2 years of growth hormone therapy // J. Pediatr. 2013. Vol. 162. P. 263–268.
Butler M.G., Sturich J., Lee J. et al. Growth standards of infants with Prader-Willi syndrome // J. Pediatr. 2011. Vol. 127. P. 687–695.
Cassidy S.B., Schwartz S., Miller J.L., Driscoll D.J. Prader-Willi syndrome // Genet. Med. 2012. Vol. 4. P. 10–26.
Eggermann T. Russell-Silver syndrome // Am. J. Med. Genet. C. Semin. Med. Genet. 2010. Vol. 154C. P. 355–364.
Eggermann T., Elbracht M., Schr?der C. et al. Congenital imprinting disorders: a novel mechanism linking seemingly unrelated disorders // J. Pediatr. 2013. Vol. 163. P. 1202–1207.
Giabicani E., Netchine I., Brioude F. New clinical and molecular insights into Silver-Russell syndrome // Curr. Opin. Pediatr. 2016. Vol. 28. P. 529–535.
Maclver N.J. Oxytocin treatment may improve infant feeding and social skills in Prader-Willi syndrome // Pediatrics. 2017. Vol. 139. N. 2. P. e20163833.
McCandless S.E. Committee on Genetics: Clinical report—health supervision for children with Prader-Willi syndrome // Pediatrics. 2011. Vol. 127. P. 195–204.
Sharkia M., Michaud S., Berthier M.T. et al. Thyroid function from birth to adolescence in Prader-Willi syndrome // J. Pediatr. 2013. Vol. 163. P. 800–805.
Spengler S., Begemann M., Br?chle N.O. et al. Molecular karyotyping as a relevant diagnostic tool in children with growth retardation with Silver-Russell features // J. Pediatr. 2012. Vol. 161. P. 933–942.
Torrado M., Foncuberta M.E., de Castro Perez M.F. et al. Change in prevalence of congenital defects in children with Prader-Willi syndrome // Pediatrics. 2013. Vol. 131. P. e544–e549.
Whitman B.Y., Myers S.E. Prader-Willi syndrome and growth hormone therapy: take a deep breath and weight the data // J. Pediatr. 2013. Vol. 162. P. 224–226.
Wolfgram P.M., Carrel A.L., Allen D.B. Long-term effects of recombinant human growth hormone therapy in children with Prader-Willi syndrome // Curr. Opin. Pediatr. 2013. Vol. 25. P. 509–514.
Bracken MB, Belanger K, Cookson WO, et al: Genetic and perinatal risk factors for asthma onset and severity: a review and theoretical analysis, Epidemiol Rev 24:176–189, 2002.
Hirschhorn JN: Genetic epidemiology of type 1 diabetes, Pediatr Diabetes 4:87–100, 2003.
International HapMap Consortium: A haplotype map of the human genome, Nature 437:1299–1320, 2005.
Lyon HN, Hirschhorn JN: Genetics of common forms of obesity: a brief overview, Am J Clin Nutr 82:215S–217S, 2005.
Manolio TA, et al: Finding the missing heritability of complex diseases, Nature 461:747–753, 2009.
Onengut-Gumuscu S, Concannon P: The genetics of type 1 diabetes: lessons learned and future challenges, J Autoimmun 25:S34–S39, 2005.
Thompson R, Drew CJ, Thomas RH: Next generation sequencing in the clinical domain: clinical advantages, practical, and ethical challenges, Adv Protein Chem Struct Biol 89:27–63, 2012.
Welter D, MacArthur J, Morales J, et al: The NHGRI GWAS catalog, a curated resource of SNP-trait associations, Nucleic Acids Res 42(database issue):D1001–D1006, 2014.
Banka S, Lederer D, Benoit V, et al: Novel KDM6A (UTX) mutations and a clinical and molecular review of the X-linked Kabuki syndrome (KS2), Clin Genet 87:252–258, 2015.
Benjamin JS, Pilarowski GO, Carosso GA, et al: A ketogenic diet rescues hippocampal memory defects in a mouse model of Kabuki syndrome, Proc Natl Acad Sci USA 114(1):125–130, 2017.
Birney E, Smith GD, Greally JM: Epigenome-wide association studies and the interpretation of disease–omics, PLoS Genet 12(6):e1006105, 2016.
Blewitt M, Whitelaw E: The use of mouse models to study epigenetics, Cold Spring Harb Perspect Biol 5(11):a017939, 2013.
Chen F, Marquez H, Kim Y-K, et al: Prenatal retinoid deficiency leads to airway hyperresponsiveness in adult mice, J Clin Invest 124(2):801–811, 2014.
Dentici ML, Di Pede A, Lepri FR, et al: Kabuki syndrome: clinical and molecular diagnosis in the first year of life, Arch Dis Child 100:158–164, 2015.
Online Mendelian Inheritance in Man (OMIM), McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore.
Pierson TM, Adams D, Bonn F, et al: Whole-exome sequencing identifies homozygous AFG3L2 mutations in a spastic ataxia-neuropathy syndrome linked to mitochondrial m-AAA proteases, PLoS Genet 7(10):e1002325, 2011.
Sincan M, Simeonov D, Adams D, et al: VAR-MD: a tool to analyze whole exome/genome variants in small human pedigrees with mendelian inheritance, Hum Mutat 33:593–598, 2012.
Taruscio D, Groft S, Cederroth H, et al: Undiagnosed Diseases Network International (UDNI): white paper for global actions to meet patient needs, Mol Genet Metab 116:223–225, 2015.
Yang Y, Muzny DM, Xia F, et al: Molecular findings among patients referred for clinical whole-exome sequencing, JAMA 312:1870–1878, 2014.